Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) has entered into an agreement with the prominent Colombian research hospital Centro Dermatológico Federico Lleras Acosta (CDFLLA) to test the effectiveness of medical cannabis for dermatological conditions.
Cannabis for Skin Care
Under the agreement, Khiron and CDFLLA will establish a clinical research partnership focused on the effectiveness of cannabis for dermatological conditions. Cannabis clinical trials performed by the parties will be the first such studies conducted in Latin America.
Khiron and CDFLLA will focus their efforts on studying and improving the methods of administering and prescribing cannabis as a potential supportive therapy for various skin conditions and symptoms.
As part of the program, the partnership will conduct training sessions, educational events and seminars focused on educating the medical community and patients on the safety and efficacy of medical cannabis.
“A growing number of healthcare professionals believe that medical cannabis provides significant benefits for patients suffering from a range of dermatological conditions. Khiron and CDFLLA are committed to developing a body of scientific research that supports these findings in order to help patients manage their skin conditions and aid doctors in making informed healthcare decisions,” CDFLLA Director Dr. Claudia Rojas said in a statement.
What Khiron will Gain from Partnership
Khiron said that the partnership reinforces its commitment to a patient-oriented operational model, which aims to engage and educate healthcare professionals and patients on the benefits of medical cannabis.
The agreement, according to Khiron, will expand the company’s efforts in the skincare sector, where it has focused on innovating and introducing CBD-based cosmeceutical products to the global market through a rigorous and research-based product development strategy.
The agreement establishes a three-year partnership between Khiron and CDFLLA, with the option to extend at the conclusion of the original period.
CDFLLA will support Khiron in performing studies on cosmetic and cosmeceutical products manufactured and marketed by Khiron through its subsidiary Kuida, the first CBD consumer brand of skin and body care products launched in Latin America.
The post Khiron, Colombian Hospital to Clinically Test Cannabis for Dermatological Conditions appeared first on Market Exclusive.